Rituximab in multiple sclerosis - Fatigue, cognition, and efficacy
Background: Multiple sclerosis (MS) is an inflammatory, demyelinating disease affecting the central nervous system. Fatigue and impaired information processing speed (IPS) are the most debilitating symptoms of MS. Natalizumab (NTZ) and rituximab (RTX), currently Sweden’s two most-prescribed drugs for MS treatment, are known to almost completely ameliorate clinical and radiological relapse activity
